FindTrial
Sign In

Clinical Observation of Qianghuo Qu Shi Qing Wen Combination Formula in Treating Influenza with Lower Respiratory Tract Infection

A Study on the Effect of Qianghuo Dampness-Clearing and Epidemic-Resolving Compound on the Prognosis of Influenza with Lower Respiratory Tract Infection in the Post-Pandemic Era Based on the "Clearing Epidemic and Detoxifying" Method

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001654
Enrollment
Unknown
Registered
2025-09-03
Start date
2024-12-20
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza with lower respiratory tract infection

Interventions

Experimental Group:Qianghuo Qushi Qingwen Mixture, oral administration, 30ml each time, three times a day + conventional Western medical treatment. The treatment duration is 5 days
Control group:The duration of basic Western medical treatment is 5 days

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older; 2. Meets diagnostic criteria for influenza complicated by acute lower respiratory infection; 3. Obtains a throat swab or sputum specimen testing positive for influenza virus via reverse transcription-polymerase chain reaction (RT-PCR); or during influenza season, presents influenza-like symptoms consistent with the disease pattern and tests positive via rapid influenza antigen detection; 4. Informed consent obtained; voluntary participation. The informed consent process must comply with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Influenza diagnosed without nucleic acid or rapid antigen testing; 2. Influenza occurring during hospitalization for other conditions; 3. Survival time < 48 hours; 4. Missing medical record documentation; 5. Severe liver and kidney dysfunction. 6. Those who are unable to give full informed consent due to intellectual or behavioral disabilities. 7. Other lesions that, based on the researcher's judgment, may reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, which can easily lead to loss to follow-up. 8. Allergic constitution, such as those with a history of allergy to two or more drugs or foods; Or those who are known to be allergic to the ingredients of this medicine. 9. Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Body temperature;Rate of progression to severe pneumonia;28-day mortality rate;—

Secondary

MeasureTime frame
White blood cell count;Neutrophil count;Lymphocyte count;C-reactive protein;Interleukin-6;Duration of mechanical ventilation;Length of stay in the ICU;Length of hospital stay;Pulmonary Imaging;—

Countries

China

Contacts

Public ContactLi Dou

Jiangsu Provincial Hospital of Traditional Chinese Medicine

963415071@qq.com13701580492

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026